UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 30, 2003
NeoPharm, Inc.
(Exact name of registrant as specified in its charter)
Delaware | | 33-90516 | | 51-0327886 |
(State or Other Jurisdiction
of incorporation) | | (Commission
File Number) | | (I.R.S. Employer
Identification No.) |
150 Field Drive, Suite 195, Lake Forest, IL 60045
(Address of principal executive offices) (Zip Code)
(847) 295-8678
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Item 7. | | Financial Statements and Exhibits |
|
(c) | Exhibits. |
| | | |
Exhibit
Number | | Description |
| | |
99.1 | | Press Release dated June 30, 2003 |
Item 9. | | Regulation FD Disclosure |
|
| On June 30, 2003, the Company issued a press release, a copy of which is attached hereto as Exhibit 99.1, providing information on the revised schedule for concluding the Registrant’s ongoing arbitration hearing with Pharmacia and Upjohn Company (now Pfizer). |
| | | |
2
SIGNATURE PAGE
Pursuant to the requirements of The Securities and Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | NEOPHARM, INC. |
| |
| |
Dated June 30, 2003 | By: | /s/ LAWRENCE A. KENYON | |
| | Chief Financial Officer
(Principal Accounting Officer and
Principal Financial Officer) |
| | | | |
3
